Company
Headquarters: Shanghai, China
Employees: 534
CEO: Dr. Yiping Li M.D.
HK$572.8 Million
HKD as of Jan. 1, 2025
US$73.7 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $113.24 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $76.33 B |
Marinomed Biotech AG | $56.13 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is relmacabtagene autoleucel, an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
JW has the following listings and related stock indices.
Stock: HKEX: 2126 wb_incandescent